Early clinical studies support their feasibility, as shown by FT596, an iPSC-derived CAR-NK engineered with IL-15 support, which demonstrated antitumor activity and a favorable safety profile in CD19+ lymphoma (Kim, 2025). The gene discussed is IL15; the disease is lymphoma.